{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:54Z","timestamp":1792451754511,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.annonc.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T16:21:13Z","timestamp":1684513273000},"page":"670-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negative\u00a0early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Falato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-4530","authenticated-orcid":false,"given":"M. Margel\u00ed","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Salvador-Bofill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gonz\u00e1lez-Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Espinosa-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Izarzugaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Esker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-D.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Parul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santhanagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1073\/pnas.1115802109","article-title":"The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium","volume":"109","author":"Balko","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.annonc.2023.05.004_bib2","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-20-4465","article-title":"Thirty years of HER3: from basic biology to therapeutic interventions","volume":"27","author":"Haikala","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2023.05.004_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","article-title":"HER3 overexpression and survival in solid tumors: a meta-analysis","volume":"105","author":"Ocana","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.annonc.2023.05.004_bib5","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A\u00a0novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.annonc.2023.05.004_bib6","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2023.05.004_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2023.05.004_bib8","doi-asserted-by":"crossref","first-page":"PD1-09","DOI":"10.1158\/1538-7445.SABCS20-PD1-09","article-title":"Safety and efficacy results from the phase 1\/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)","volume":"81","author":"Krop","year":"2021","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2023.05.004_bib9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2022.40.16_suppl.1002","article-title":"Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer","volume":"40","author":"Krop","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2023.05.004_bib10","doi-asserted-by":"crossref","first-page":"PD1-03","DOI":"10.1158\/1538-7445.SABCS18-PD1-03","article-title":"Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: updated results of a phase 1\/2 trial","volume":"79","author":"Masuda","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2023.05.004_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCO.0000000000000583","article-title":"Window of opportunity trials for biomarker discovery in breast cancer","volume":"31","author":"Arnedos","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.annonc.2023.05.004_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2015.12.005","article-title":"Window of opportunity studies: do they fulfil our expectations?","volume":"43","author":"Schmitz","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2023.05.004_bib13","first-page":"S15","article-title":"15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): a SOLTI biomarker analysis","volume":"31","author":"Gonz\u00e1lez-Farr\u00e9","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/annonc\/mdx647","article-title":"A\u00a0predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade","volume":"29","author":"Nuciforo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.05.004_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.638482","article-title":"SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a HER3 directed antibody drug conjugate, in patients with early breast cancer","volume":"11","author":"Pascual","year":"2021","journal-title":"Front Oncol"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2023.05.004_bib16","first-page":"S55","article-title":"SOLTI-1805 TOT-HER3 trial: a window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment na\u00efve, early breast cancer","volume":"33","author":"Oliveira","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2023.05.004_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.annonc.2023.05.004_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.annonc.2023.05.004_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2023.05.004_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2023.05.004_bib21","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A\u00a0comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2023.05.004_bib22","series-title":"SAM: Significance Analysis of Microarrays (5.0","author":"Seo","year":"2014"},{"issue":"9","key":"10.1016\/j.annonc.2023.05.004_bib23","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2023.05.004_bib25","first-page":"S808","article-title":"Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HR+\/HER2- metastatic breast cancer (mBC)","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2023.05.004_bib26","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.annonc.2022.03.277","article-title":"Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial","volume":"33","author":"Mosele","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.05.004_bib27","series-title":"Mechanism of action and resistance to trastuzumab deruxtecan in patients with metastatic breast cancer: the DAISY trial","author":"Andre","year":"2022"},{"issue":"25","key":"10.1016\/j.annonc.2023.05.004_bib28","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","article-title":"Luminal B breast cancer: molecular characterization, clinical management, and future perspectives","volume":"32","author":"Ades","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9938","key":"10.1016\/j.annonc.2023.05.004_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.annonc.2023.05.004_bib30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial","volume":"6","author":"Yee","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2023.05.004_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1574892811666160418123221","article-title":"HER3 and its ligand, heregulin, as targets for cancer therapy","volume":"11","author":"Kawakami","year":"2016","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib33","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s41598-020-59514-1","article-title":"Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers","volume":"10","author":"Ogden","year":"2020","journal-title":"Sci Rep"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2023.05.004_bib34","article-title":"Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)","volume":"82","author":"Odena","year":"2022","journal-title":"Cancer Res"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2023.05.004_bib35","article-title":"Genetic determinants of response to patritumab deruxtecan in hormone receptor positive (HR positive), HER2 negative breast cancer: a correlative analysis from SOLTI-TOT-HER3 trial","volume":"83","author":"Bras\u00f3-Maristany","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1172\/JCI126598","article-title":"U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation","volume":"130","author":"Haratani","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2023.05.004_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jnci\/djab057","article-title":"Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer","volume":"114","author":"Chic","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.004_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41523-021-00351-4","article-title":"Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial","volume":"7","author":"Pascual","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.annonc.2023.05.004_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423006853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423006853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T06:35:04Z","timestamp":1707546904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423006853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0923753423006853"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.05.004","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negative\u00a0early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}